Bristol-Myers Squibb (BMY) is a Healthcare company in the Drug Manufacturers General industry. It has a market capitalization of $127.02B, a trailing price-to-earnings ratio of 10.0 and a free-cash-flow yield of 10.1%. Over the most recent reported fiscal year, revenue declined 0.2% and free cash flow per share fell 8.4%. Nama's AI scorecard rates it Buy, 6.8 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Buy · 6.8/10
Positive, at the low end of Buy. As of Nov 7, 2026.
Momentum
Leading · +28.0% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-23.7%
How far the last close sits under the highest price of the past five years.
Market cap
$127.02B
Trailing P/E
10.0
Price / book
5.4
Price / sales
2.5
FCF yield
10.1%
Dividend yield
4.1%
Gross margin
69.2%
Operating margin
29.2%
Net margin
18.5%
Revenue growth (YoY)
-0.2%
Revenue growth (3-yr annual)
+1.4%
EPS growth (YoY)
+439.5%
FCF/share growth (YoY)
-8.4%
Beta
0.2
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers General
BMY earnings
Next report: Feb 4, 2027 (Q4 2026, EPS estimate $1.50).
Beat the EPS estimate in 4 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Oct 29, 2026
$1.35
$1.17
+15.4%
$13.07B
Q2 2026
Jul 30, 2026
$2.04
$1.60
+27.5%
$12.97B
Q1 2026
Apr 30, 2026
$1.58
$1.42
+11.3%
$11.49B
Q4 2025
Feb 5, 2026
$1.26
$1.20
+5.0%
$12.50B
BMY analyst price target
Median target $65.50 from 24 analysts, ranging $40.00 – $80.00.
Nama's AI scorecard currently rates Bristol-Myers Squibb Buy (6.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is BMY's P/E ratio?
Bristol-Myers Squibb trades at a trailing price-to-earnings ratio of 10.0.
When does BMY report earnings?
Bristol-Myers Squibb's next scheduled report is on Feb 4, 2027. Analysts expect EPS of $1.50.
What is the BMY price target?
The median analyst price target from 24 analysts is $65.50, with a range of $40.00 – $80.00.
Is BMY Shariah compliant?
Nama's AAOIFI-style screen reads Bristol-Myers Squibb as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does BMY pay a dividend?
Yes — Bristol-Myers Squibb's dividend yield is 4.1%.